The CARDIOLIPID Plan: A Cardiovascular Risk-centred Implementation Framework for the Diagnosis and Management of Dyslipidaemia: Experts’ Proposal
Open Access
- 9 July 2026
- journal article
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
Abstract
Dyslipidaemia remains a major contributor to cardiovascular morbidity and mortality, despite the availability of effective lipid-lowering therapies and well-established European Society of Cardiology/European Atherosclerosis Society guidelines. In clinical practice, the implementation of these recommendations is often suboptimal, with persistent therapeutic inertia and fragmented decision-making processes. The CARDIOLIPID Plan is a proposed cardiovascular risk-centred implementation framework designed to support the practical application of guideline-based care. The model integrates two key components of clinical decision-making: comprehensive cardiovascular risk assessment (CARDIO) and personalised lipid-lowering intervention (LIPID), structured into a sequential and clinically applicable pathway. While the individual elements of the CARDIOLIPID Plan are derived from current evidence and guideline recommendations, their organisation within this framework reflects an interpretation by experts aimed at improving clarity, usability and clinical implementation. The model emphasises early and appropriate treatment intensification, reduction of therapeutic inertia and a holistic, patient-centred approach to cardiovascular risk management. The CARDIOLIPID Plan may serve as a practical tool to enhance the translation of evidence into clinical practice. However, as a conceptual and implementation-oriented framework, it requires validation in real-world settings to assess its impact on treatment outcomes and cardiovascular risk reduction.Keywords
This publication has 86 references indexed in Scilit:
- Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle EastAdvances in Therapy, 2025
- Learnings from Implementation Strategies to Improve Lipid ManagementCurrent Cardiology Reports, 2025
- 2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)Drugs, 2024
- Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?Current Atherosclerosis Reports, 2024
- Statin Intolerance: An Overview for Clinicians2023
- Familial Hypercholesterolemia: Global Burden and ApproachesCurrent Cardiology Reports, 2021
- Periodontitis, Blood Pressure, and the Risk and Control of Arterial Hypertension: Epidemiological, Clinical, and Pathophysiological Aspects—Review of the Literature and Clinical TrialsCurrent Hypertension Reports, 2021
- Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participantsAmerican Heart Journal, 2019
- Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 DiabetesJAMA Cardiology, 2017
- Comparison of Novel Risk Markers for Improvement in Cardiovascular Risk Assessment in Intermediate-Risk IndividualsJAMA, 2012